• 2024 First-Quarter reported sales growth of 2.3% to $21.4 Billion with operational growth of 3.9%* andadjusted operational growth of 4.0%*
o Adjusted operational growth excluding COVID-19 Vaccine of 7.7%*
• 2024 First-Quarter Earnings per share (EPS) increased to $2.20 and adjusted EPS increased to $2.71 or12.4%*
• Company increasing the midpoint for Full-Year 2024 operational sales5 and adjusted operational EPSguidance
New Brunswick, N.J. (April 16, 2024) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2024.“Johnson & Johnson’s solid first quarter performance reflects our sharpened focus and the progress in our portfolio andpipeline,” said Joaquin Duato, Chairman and Chief Executive Officer. “Our impact across the full spectrum of healthcare isunique in our industry, and the milestones achieved this quarter reinforce our position as an innovation powerhouse.”
Unless otherwise noted, the financial results and earnings guidance included below reflect the continuing operations ofJohnson & Johnson.
Overall Financial Results 
First Quarter 2024 Segment Commentary:
Operational sales* reflected below excludes the impact of translational currency.Adjusted operational sales* reflected below excludes the net impact of acquisitions and divestitures and translational currency.
Innovative Medicine
Innovative Medicine worldwide operational sales, excluding the COVID-19 Vaccine, grew 8.3%*. Growth was driven byDARZALEX (daratumumab), ERLEADA (apalutamide), CARVYKTI (ciltacabtagene autoleucel), TECVAYLI (teclistamabcqyv) and Other Oncology in Oncology, UPTRAVI (selexipag) and OPSUMIT (macitentan) in Pulmonary Hypertension,TREMFYA (guselkumab) in Immunology, and SPRAVATO (esketamine) in Neuroscience. Including the COVID-19 Vaccine,Innovative Medicine worldwide operational sales grew 2.5%*.
MedTech
MedTech worldwide operational sales grew 6.3%* driven primarily by electrophysiology products and Abiomed inCardiovascular, previously referred to as Interventional Solutions, and wound closure products in General Surgery.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to builda world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive,and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned toinnovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, andprofoundly impact health for humanity. Learn more at https://www.jnj.com/.
点击阅读原文了解更多详情